What happened
T&R Biofab filed provisional (unaudited) consolidated results for Q3 2026: revenue of US$6.7M (+28.1% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$6.7M |
|---|---|
| Revenue vs a year earlier | +28.1% |
| Period | Q3 2026 (consolidated) |
| Filed | 2026-10-19, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20261019900118 → open original filing |
Source: DART. Information only, not investment advice.